Eurofins Viracor BioPharma Announces Relocation to New State-of-the-Art Facility
29 August 2025
Lenexa, KS – Eurofins Viracor BioPharma Services, a recognized leader in analytical testing and clinical trial services, is proud to announce the infrastructure enhancement of its headquarters and laboratory operations to a new, custom-built 96,000 sq. ft. facility in Lenexa, Kansas, scheduled for completion in September 2025. This strategic move, although only a few miles from their previous location, marks a significant milestone in the company’s continued growth and commitment to delivering cutting-edge solutions to the biopharmaceutical industry.
Eurofins Viracor BioPharma Services was formally spun out of Viracor in 2020 to focus exclusively on supporting biopharmaceutical sponsors with specialized analytical and clinical trial services. Until now, both companies operated from the same facility, but with Eurofins Viracor BioPharma’s relocation to a new, dedicated space, each organization can better concentrate on its core market—Viracor on clinical diagnostics and Eurofins Viracor BioPharma on biopharma services. This separation allows both to take full advantage of the strategic benefits offered by the Kansas City region, including access to top-tier scientific talent, centralized logistics, and a thriving life sciences ecosystem that fosters innovation and growth.
The new facility supports the increasing demand for advanced testing services, particularly in the areas of sequencing and precision medicine, cell-based assays, high-complexity flow cytometry, vaccine development and biomarker analysis. These capabilities are essential for evaluating safety and efficacy endpoints such as immunogenicity, neutralizing antibodies, target engagement, and mechanism-of-action studies and unlocking disease biology through next-generation (NGS) and RNA sequencing, which are critical to the development and validation of novel therapeutics.
Eurofins Viracor BioPharma’s expanded infrastructure will also enhance its ability to support custom assay development, GLP/GCLP-compliant assay validation, and clinical sample testing across all phases of drug development as well as provide space for new service line launches in the future. The facility will house leading-edge analytical platforms, integrated automation systems, and expanded biorepository capacity, enabling faster turnaround times, increased throughput, and improved data integrity.
The relocation underscores Eurofins Viracor BioPharma Services’ commitment to investment, innovation, scalability, and operational excellence. This strategic expansion enables the company to offer a broader range of services and deeper scientific expertise, while maintaining the quality, agility, and responsiveness it is known for. The facility was thoughtfully designed to meet client needs and improve staff efficiency, optimizing sample flow through the lab and reinforcing the belief that life-enhancing therapies require exceptional solutions.
Eurofins Viracor BioPharma’s scientific team brings decades of experience in molecular biology, oncology, virology, cell biology, infectious disease and immunology, offering consultative support to sponsors navigating complex regulatory and scientific challenges. The company’s collaborative approach and robust quality systems ensure reliable, reproducible results that accelerate clinical development timelines and ultimately help facilitate the advancement of critical, life-enhancing therapies.
As part of the Eurofins Clinical Trial Solutions network, Eurofins Viracor BioPharma Services is uniquely positioned to provide integrated solutions cross bioanalytical, central laboratory, pathology, specialty testing services, and clinical IMP packaging, supporting global clinical trials with precision, accuracy and efficiency.
To learn more about Eurofins Viracor BioPharma Services’ expanded capabilities and new facility, please visit www.eurofinsvbp.com.
For further information:
Jennifer Absher
Director of Marketing
Eurofins Viracor BioPharma
Jennifer.Absher@VBP.Eurofinsus.com
919-744-7884
Frequently Asked Questions
Why are we moving?
Our relocation is consistent with our organizational goal of providing more comprehensive solutions for our clients. Our testing needs, both current and future, are rapidly increasing, and we are on the verge of surpassing the capacity of our current location. Relocating to a new site affords us the opportunity to design a purpose-built facility where we can maximize flexibility and efficiency of operations as well as ensure we have the space needed for future growth. Additionally, we are adding new, state-of-the-art analytical testing platforms, processing automation, and storage technology to ensure we are well positioned to meet the changing needs of our clients.
Did the move encompass all business units, all equipment, testing, personnel, etc.?
The Eurofins Viracor BioPharma company headquarters, all laboratory testing equipment, and personnel will be moving to the new facility in Lenexa, KS.
When is the actual date of the transfer of operations?
While certain factors such as weather may have an impact on our actual date of transfer, the project is currently on target for completion and our new lab is tentatively scheduled to open on September 26th, 2025. However, movement of other functions and personnel will be done in phases throughout the rest of the year, to make the transition more efficient and orderly.
Will any services temporarily be unavailable during the move?
We do not expect to experience any disruption of critical services during the relocation. We also do not expect any significant delays to ongoing client projects/studies as a function of the move. We have plans to establish temporary duplicate systems at both sites to maintain services through qualification of all new or relocated systems.
Does all testing need to be re-validated at the new location?
No. Notice of our relocation move has been made to regulators and individual clients. We are following a Validation Master Move Plan we created that outlines our phased process. This includes plans to move and qualify instrumentation so that we will have qualified instruments at both locations. Once an instrument is on-line at the new facility, we will transfer the assays that are currently validated and active. There will be sufficient redundant systems so testing will continue at our current address until all instruments are qualified. After completion of the transfer, clinical trial samples will be transferred while maintaining required storage conditions, and analysis started at the new facility. A final report in support of the Validation Master Move Plan will be written to document the outcome of the equipment and assay transfers to the new location, which will be shared with clients upon request.
Will our laboratory license/certification numbers change?
Yes. We are working with the accrediting bodies to get new certifications and will share our updated license and certification numbers with clients.
Who will handle the actual movement of analytical testing equipment?
The move will be handled by a professional service with an excellent reputation for moving laboratory equipment and systems, and requalification will be performed by our highly qualified Biomedical Equipment and Metrology teams in conjunction with vendor service technicians. Additionally, original equipment manufacturer service technicians will be brought in to prepare more sensitive instruments for shipment and to reinstall each system at our new location.
How will Eurofins Viracor BioPharma handle transfer of samples that are already in long-term storage at the old facility?
All study material currently stored at Eurofins Viracor BioPharma will be maintained and transported under controlled conditions to the new facility.
How much notice will be provided for when the shipping address for biological samples will change?
Clients will be notified six weeks before the date when they should begin using our new address for all future sample shipments.
In addition, the new facility is less than six miles from our current location, and we will have our own transport service available if samples arrive at the new site prior to transfer of testing services. Similarly, any samples that are delivered to our old location after the move will be transported to the new site via the same service.